Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults
By Elana Gotkine HealthDay Reporter
FRIDAY, May 9, 2025 -- mRNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines against several influenza strains and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published online May 7 in the Journal of the American Medical Association.
Amanda K. Rudman Spergel, M.D., from Moderna Inc. in Cambridge, Massachusetts, and colleagues examined the immunogenicity and safety of an investigational mRNA-1083 vaccine against seasonal influenza and SARS-CoV-2 in adults aged 50 years and older in a trial conducted across 146 U.S. sites. Adults aged 65 years and older (4,017 participants) and 50 to 64 years (3,998 participants) were randomly assigned to receive mRNA-1083 plus placebo or coadministered licensed quadrivalent seasonal influenza (65 years and older: high-dose quadrivalent inactivated influenza vaccine [HD-IIV4]; 50 to 64 years: standard-dose IIV4 [SD-IIV4]) and COVID-19 (mRNA-1273) vaccines.
The researchers found that based on the lower bound of the 97.5 percent confidence interval of the geometric mean ratio greater than 0.667 and lower bound of the 97.5 percent confidence interval of the seroconversion/seroresponse rate difference greater than −10 percent, noninferior immunogenicity of mRNA-1083 was demonstrated against all vaccine-matched influenza and SARS-CoV-2 strains. Higher immune responses were elicited by mRNA-1083 than SD-IIV4 (50 to 64 years) for all four influenza strains and HD-IIV4 (65 years and older) for three influenza strains, and against SARS-CoV-2 (all ages). Relative to comparators, solicited adverse reactions were numerically higher in frequency and severity after mRNA-1083 vaccination than comparators in both age cohorts.
"This pivotal phase 3 study demonstrated the noninferiority of a single mRNA-1083 dose in adults 50 years and older," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Moderna, which is developing the mRNA-1083 vaccine and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Further Support and Information on COVID-19
Read this next
Wildfire-Induced Changes in Behavior Affect Spread of Airborne Disease
WEDNESDAY, June 25, 2025 -- Wildfire-induced deterioration of air quality leads to a substantial increase in indoor activities, fostering conditions conducive to transmission of...
Worse Outcomes Seen for Unvaccinated Patients Hospitalized With COVID-19, AKI
WEDNESDAY, June 18, 2025 -- For patients hospitalized with COVID-19 infection and acute kidney injury (AKI), those who are unvaccinated have worse outcomes in terms of kidney...
Decline in Youth Physical Fitness Seen in Association With Pandemic
FRIDAY, June 13, 2025 -- During the early days of the COVID-19 pandemic, there was a decline in the physical fitness of U.S. youth, according to a study published online June 4 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.